Under Trump's executive order, marijuana will be moved from Schedule I, which includes banned substances such as heroin, LSD, ...

The move to reclassify cannabis from a Schedule I to a Schedule III drug could spark new studies into pain, aging and women's health, Dr. Staci Gruber tells GBH's All Things Considered.

AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...

A groundbreaking discovery led by the University of St Andrews has found a way to turn ordinary household plastic waste into the building block for anti-cancer drugs.

Moving cannabis to a category of drugs that includes some common medicines will have implications for research, businesses ...

Tenofovir alafenamide (Vemlidy) for the initial treatment of chronic hepatitis B may confer modestly higher rates of complete ...

Marijuana’s classification as one of the most dangerous and habit-forming substances has long drawn criticism.

Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination ...

A new scale for grading ocular adverse events in oncology trials addresses ambiguities in CTCAE version 5 and includes dose modification recommendations. The scale, implemented in the I-SPY 2 trial, ...

Comprehensive genomic testing in routine cancer care pathways has created the need to interpret the consequences of somatic (acquired) genomic variants beyond the currently well-characterised driver ...

The Food and Drug Administration granted accelerated approval on Wednesday for a new drug developed by researchers at the Broad Institute that treats non-small cell lung cancer — the most common type ...

The company, which had no revenue last year and 7.5 billion won ($5.1 million) in sales for the first nine months of this year with widening losses, boasts a $2.9 billion market cap. South Korea’s ...